+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Active Pharmaceutical Ingredient Market (2021-2026) by Ingredient, Synthesis Type, Molecule Type, Product Type, Manufacturing Type, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 174 Pages
  • December 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5544134
The Global Active Pharmaceutical Ingredient Market is estimated to be USD 199.25 Bn in 2021 and is expected to reach USD 271.97 Bn by 2026, growing at a CAGR of 6.42%.



Market Dynamics

Key factors such as the increasing incidence of chronic diseases with a rising geriatric population have significantly increased the Global Active Pharmaceutical Ingredient (API) market. Similarly, the growing dependence on API formulation in developing nations with lower costs and the rising investments of the pharmaceutical companies in API drugs also benefit market growth. Moreover, the advancements in API manufacturing with improvements in the API synthesis process and the evolving biosimilars market is expected to create opportunities in the Global Active Pharmaceutical Ingredient Market.

However, the price control policies and high costs of manufacturing API drugs are restraining the market's growth.

Market Segmentation

  • The Global Active Pharmaceutical Ingredient Market is segmented further based on Ingredient, Synthesis Type, Molecule Type, Product Type, Manufacturing Type, And Geography.
  • By Ingredient, the market is classified as Branded Active Pharmaceutical Ingredients and Generic Active Pharmaceutical Ingredients.
  • By Synthesis Type, the market is classified as Synthetic and Biotech.
  • By Molecule Type, the market is classified as Small Molecule and Large Molecule.
  • By Potency Type, the market is classified as Potent High API and Low Potent API.


By Manufacturing Type, the market is classified as Captive API and Merchant API.
  • By Geography, America is projected to lead the market.

Recent Developments

1. Pfizer US has signed an agreement with Gilead Sciences to manufacture and supply Gilead's antiviral drug (Remdesivir) for treatment COVID-19. - 7th August 2020
2. Novartis Switzerland acquired Aspen's Japanese operations to strengthen its global generics and off-patent medicines market. - 8th August 2020

Company Profiles

Some of the companies covered in this report are Cipla, Inc., Merck & Co., Inc., Albemarle Corporation, Pfizer Inc, Novartis, Sanofi, Abbvie, Aurobindo Pharma, Viatris Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Active Pharmaceutical Ingredient Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Active Pharmaceutical Ingredient Market

What is the estimated value of the Global Active Pharmaceutical Ingredient Market?

The Global Active Pharmaceutical Ingredient Market was estimated to be valued at $199.25 Billion in 2021.

What is the growth rate of the Global Active Pharmaceutical Ingredient Market?

The growth rate of the Global Active Pharmaceutical Ingredient Market is 6.4%, with an estimated value of $271.97 Billion by 2026.

What is the forecasted size of the Global Active Pharmaceutical Ingredient Market?

The Global Active Pharmaceutical Ingredient Market is estimated to be worth $271.97 Billion by 2026.

Who are the key companies in the Global Active Pharmaceutical Ingredient Market?

Key companies in the Global Active Pharmaceutical Ingredient Market include AbbVie, Inc., Albemarle Corporation, AstraZeneca plc, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Bristol, Myers Squibb Company, Cipla, Inc. and Eli Lilly and Company.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Incidence of Diseases
4.1.2 Growing Baby Boomers and Millennials Medical Expenditure
4.1.3 Growing Demand of API Formulation and Generics in Developing Countries
4.2 Restraints
4.2.1 High Manufacturing Costs
4.2.2 Regulatory Policies and Unfavourable Drug Price Control Policies
4.3 Opportunities
4.3.1 Companies Investemnt in Development of New Drugs and Precision Medicine
4.3.2 Growth In The Contract Manufacturing Organizations (CMOs)
4.3.3 Emergence Of Biosimilars Market
4.3.4 Growing Artificial Intelligence (AI) Adoption for Drug Discovery
4.4 Challenges
4.4.1 Drug Price Control Policies Across Various Countries
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global Active Pharmaceutical Ingredient Market, By Ingredient Type
6.1 Introduction
6.2 Branded Active Pharmaceutical Ingredients
6.3 Generic Active Pharmaceutical Ingredients
7 Global Active Pharmaceutical Ingredient Market, By Type
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Hormones & Growth Factors
7.3.3 Recombinant Vaccines
7.3.4 Therapeutic Enzymes
7.3.5 Others
8 Global Active Pharmaceutical Ingredient Market, By Molecule Type
8.1 Introduction
8.2 Small Molecule
8.3 Large Molecule
9 Global Active Pharmaceutical Ingredient Market, By Potency Type
9.1 Introduction
9.2 High Potent APIs
9.3 Low Potent APIs
10 Global Active Pharmaceutical Ingredient Market, By Manufacturer Type
10.1 Introduction
10.2 Captive API
10.3 Merchant API
11 Global Active Pharmaceutical Ingredient Market, By Geography
11.1 Introduction
11.2 America
11.2.1 Argentina
11.2.2 Brazil
11.2.3 Canada
11.2.4 Chile
11.2.5 Colombia
11.2.6 Mexico
11.2.7 Peru
11.2.8 United States
11.2.9 Rest of Americas
11.3 Europe
11.3.1 Austria
11.3.2 Belgium
11.3.3 Denmark
11.3.4 Finland
11.3.5 France
11.3.6 Germany
11.3.7 Italy
11.3.8 Netherlands
11.3.9 Norway
11.3.10 Poland
11.3.11 Russia
11.3.12 Spain
11.3.13 Sweden
11.3.14 Switzerland
11.3.15 United Kingdom
11.3.16 Rest of Europe
11.4 Middle East and Africa
11.4.1 Egypt
11.4.2 Israel
11.4.3 Qatar
11.4.4 Saudi Arabia
11.4.5 South Africa
11.4.6 United Arab Emirates
11.4.7 Rest of MEA
11.5 Asia-Pacific
11.5.1 Australia
11.5.2 Bangladesh
11.5.3 China
11.5.4 India
11.5.5 Indonesia
11.5.6 Japan
11.5.7 Malaysia
11.5.8 Philippines
11.5.9 Singapore
11.5.10 South Korea
11.5.11 Sri Lanka
11.5.12 Thailand
11.5.13 Taiwan
11.5.14 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements
13 Company Profiles
13.1 AbbVie, Inc.
13.2 Albemarle Corporation
13.3 AstraZeneca plc
13.4 Aurobindo Pharma Limited
13.5 Boehringer Ingelheim International GmbH
13.6 Bristol-Myers Squibb Company
13.7 Cipla, Inc.
13.8 Dr. Reddy's Laboratories Ltd
13.9 Eli Lilly and Company
13.10 Glaxosmithkline Plc
13.11 Hoffmann-La Roche Ltd.
13.12 Merck & Co., Inc.
13.13 Novartis Ag
13.14 Pfizer, Inc.
13.15 Roche Holding AG
13.16 Sanofi
13.17 Shenzhen Hepalink Pharmaceutical Co., Ltd.
13.18 Sun Pharmaceutical Industries Ltd.
13.19 Teva Active Pharmaceutical Ingredients
13.20 Viatris Inc
13.21 Zhejiang Huahai Pharmaceutical Co., Ltd
14 Appendix
14.1 Questionnaire

Companies Mentioned

  • AbbVie, Inc.
  • Albemarle Corporation
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Glaxosmithkline Plc
  • Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer, Inc.
  • Roche Holding AG
  • Sanofi
  • Shenzhen Hepalink Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Active Pharmaceutical Ingredients
  • Viatris Inc
  • Zhejiang Huahai Pharmaceutical Co., Ltd